People: XOMA Corp (XOMA.W)

Summary

Name	Age	Since	Current Position
W. Denman Van Ness	69	2011	Chairman of the Board, Lead Independent Director
John Varian	53	2012	Chief Executive Officer, Director
Fred Kurland	62	2009	Chief Financial Officer, Vice President - Finance
Patrick Scannon	65	2011	Executive Vice President, Chief Scientific Officer, Director
Paul Rubin	59	2012	Senior Vice President - Research and Development, Chief Medical Officer
Tom Klein		2013	Chief Commercial Officer
Joseph Limber	59	2012	Director
Kelvin Neu		2012	Director
William Bowes	86	1986	Independent Director
Peter Hutt	77	2005	Independent Director
Timothy Walbert	45	2010	Independent Director
Jack Wyszomierski	56	2010	Independent Director

» Insider Trading

Biographies

Name	Description
W. Denman Van Ness	Mr. W. Denman Van Ness is Chairman of the Board, Lead Independent Director of Xoma Corp. He has been a director since October of 1981 and was appointed Lead Independent Director in January of 2008 and Chairman of the Board in August of 2011. He is Chairman of Hidden Hill Advisors, a venture capital consulting firm. From April of 1996 through October of 1999, he was a Managing Director of CIBC Capital Partners, an international merchant banking organization. From 1986 to 1996, Mr. Van Ness was a General Partner of Olympic Venture Partners II and Rainier Venture Partners, venture capital funds, and from 1977 until 1985, he was a General Partner of the venture capital group at Hambrecht & Quist, the manager of several venture capital funds.
John Varian	Mr. John W. Varian is Chief Executive Officer, Director of XOMA Corporation. He was appointed Chief Executive Officer in January 2012 after serving as Interim Chief Executive Officer since August 31, 2011. He has been a director of the Company since December of 2008. He served as Chief Operating Officer of Aryx Therapeutics from December of 2003 to August of 2011. Prior to joining Aryx Therapeutics, Mr. Varian was the Chief Financial Officer of Genset S.A., where he was a key member of the team negotiating the company’s sale to Serono S.A. in 2002. Mr. Varian served on the Board of Nventa Biopharmaceuticals Corporation until the company merged with Akela Pharma Inc. in March of 2009. From October of 1998 to April of 2000, Mr. Varian served as Senior Vice President, Finance and Administration of Elan Pharmaceuticals, Inc., joining the company as part of its acquisition of Neurex Corporation. Prior to the acquisition, he served as Neurex Corporation’s Chief Financial Officer from June of 1997 until October of 1998. From 1991 until 1997, Mr. Varian served as the Vice President Finance and Chief Financial Officer of Anergen Inc. Mr. Varian was an Audit Principal/Senior Manager at Ernst & Young from 1987 until 1991 where he focused on life sciences. He is a founding member of the Bay Area Bioscience Center and a former chairman of the Association of Bioscience Financial Officers International Conference. Mr. Varian received a B.B.A. degree from Western Michigan University.
Fred Kurland	Mr. Fred Kurland is Chief Financial Officer, Vice President - Finance of Xoma Corp. He joined the Company on December 28, 2008. Mr. Kurland is responsible for directing the Company’s financial strategy, accounting, financial planning and investor relations functions. He has more than 30 years of experience in biotechnology and pharmaceutical companies including Aviron/MedImmune, Protein Design Labs and Syntex/Roche. Prior to joining XOMA, and between 2002 and 2008, Mr. Kurland served as Chief Financial Officer of Bayhill Therapeutics, Inc., Corcept Therapeutics Incorporated and Genitope Corporation. From 1998 to 2002, Mr. Kurland served as Senior Vice President and Chief Financial Officer of Aviron, the developer of FluMist, which was acquired by MedImmune in 2001. From 1996 to 1998, he was Vice President and Chief Financial Officer of Protein Design Labs, Inc., an antibody design company, and from 1995 to 1996, he served as Vice President and Chief Financial Officer of Applied Immune Sciences, Inc. Mr. Kurland also held a number of financial management positions at Syntex Corporation, a pharmaceutical company acquired by Roche, including Vice President and Controller between 1991 and 1995. He received his J.D. and M.B.A. degrees from the University of Chicago and his B.S. degree from Lehigh University.
Patrick Scannon	Dr. Patrick J. Scannon, M.D., Ph.D., is Executive Vice President, Chief Scientific Officer, Director of XOMA Corporation. He is one of the Company’s founders and has served as a director since its formation. Dr. Scannon became Executive Vice President and Chief Scientific Officer in February of 2011. Previously he was Executive Vice President and Chief Medical Officer beginning in March of 2009 and served as Executive Vice President and Chief Biotechnology Officer from May of 2006 until March of 2009, Chief Scientific and Medical Officer from March of 1993 until May of 2006, Senior Vice President from May of 1999 to May of 2006, Vice Chairman, Scientific and Medical Affairs from April of 1992 to March of 1993 and President from the Company’s formation until April of 1992. Dr. Scannon served on the National Biodefense Science Board, reporting to the Secretary of the Department of Health and Human Services from 2007 to January of 2012. He also serves on the Defense Sciences Research Council for the Defense Advanced Research Projects Agency (DARPA) and on the Threat Reduction Advisory Committee for the Department of Defense. In 2007, he was appointed to the Board of Directors of Pain Therapeutics, Inc., a biopharmaceutical company. From 1979 until 1981, Dr. Scannon was a clinical research scientist at the Letterman Army Institute of Research in San Francisco. A Board-certified internist, Dr. Scannon holds a Ph.D. in organic chemistry from the University of California, Berkeley and an M.D. from the Medical College of Georgia.
Paul Rubin	Dr. Paul D. Rubin, M.D., is Senior Vice President - Research and Development, Chief Medical Officer of XOMA Corporation, since May 24, 2012. Dr. Rubin joined the Company in June 2011. Prior to joining XOMA, Dr. Rubin was Chief Medical Officer at Funxional Therapeutics Ltd. He was Chief Executive Officer of Resolvyx Pharmaceuticals, Inc. from 2007 to 2009 and President and Chief Executive Officer of Critical Therapeutics, Inc. from 2002 to 2007. From 1996 to 2002, Dr. Rubin served as Senior Vice President, Development, and later as Executive Vice President, Research & Development at Sepracor. He was responsible for the development of all of Sepracor's internally developed approved products including Xopenex®, Lunesta®, Xopenex HFA® and Brovana®. From 1993 to 1996, Dr. Rubin held senior level positions at Glaxo-Wellcome Pharmaceuticals, most recently as Vice President of Worldwide Clinical Pharmacology and Early Clinical Development. During his tenure with Abbott from 1987 to 1993, Dr. Rubin served as Vice President, Immunology and Endocrinology, where he advanced zilueton, the first 5-lipoxygenase inhibitor, from discovery to approval for the treatment of asthma. Dr. Rubin received a BA from Occidental College and his M.D. from Rush Medical College. He completed his training in internal medicine at the University of Wisconsin.
Tom Klein	Mr. Tom Klein has been appointed as Chief Commercial Officer of XOMA Corporation. During his tenure with Genentech, Mr. Klein worked closely with both the Roche and Genentech teams to develop and execute commercial integration plans that met the needs of each company in their respective territories. Mr. Klein joined Genentech from Roche, where he had direct oversight over the Roche Hepatology and HIV Sales and Marketing teams and was responsible for ensuring affiliate and global strategic alignment. Prior to his 12 years with Roche, Mr. Klein spent 11 years with Westwood-Squibb/Bristol Myers-Squibb in a several sales and product management roles. Mr. Klein has launch experience in both the specialty and primary care markets, most recently with Boniva(R) (ibandronate sodium) for the treatment of osteoporosis in postmenopausal women. He also has been responsible for the category growth of Pegasys(R) (peginterferon alpha-2a) in HCV and market leadership of Pulmozyme(R) (dornase alfa) in cystic fibrosis, a rare disease area. Mr. Klein has a BA, Marketing, from Pennsylvania State University and an MBA, Management from Temple University.
Joseph Limber	Mr. Joseph M. Limber is appointed as Director of Xoma Corp., effective December 12, 2012. Mr. Limber led a expansion of Prometheus Laboratories' business, both organically through internally developed products and through product acquisitions. He led negotiations to acquire exclusive U.S. commercial rights to ENTOCORT EC from AstraZeneca and Proleukin from Novartis, as well as the purchase of Lotronex from GlaxoSmithKline. Prior to joining Prometheus in 2003, Mr. Limber was a consultant and interim Chief Executive Officer of Deltagen, Inc., a provider of drug discovery tools and services to the biopharmaceutical industry. From April 1998 to December 2002, Mr. Limber was President and Chief Executive Officer of ACLARA BioSciences, Inc., a developer of assay technologies and lab-on-a-chip systems for life science research. From 1996 to 1998, he was the President and Chief Operating Officer of Praecis Pharmaceuticals, a biotechnology company focused on the discovery and development of pharmaceutical products. Prior to Praecis, Mr. Limber served as Executive Vice President of SEQUUS Pharmaceuticals, Inc. He also held management positions in marketing and sales with Syntex Corporation and with Ciba-Geigy Corporation. Prometheus Laboratories was acquired by Nestlé Health Science in July of 2011. Mr. Limber has held seats on the Boards of Directors at numerous companies, including Panacos Pharmaceuticals, Molecular Insight Pharmaceuticals and CombiMatrix Corporation.
Kelvin Neu	Dr. Kelvin Neu is appointed as Director of Xoma Corp., effective July 19, 2012. Dr. Neu, M.D. is a Managing Director at Baker Bros. Investments. Baker Bros. Investments manages long-term investment funds focused on publicly traded life sciences companies, for university endowments and foundations. Dr. Neu has previously served as a Director of Anormed Inc. and diaDexus Inc. Dr. Neu holds an holds an A.B. (Summa Cum Laude) in Molecular Biology from Princeton University, and an M.D. from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology. Dr Neu also spent three years in the Immunology Ph.D. program at Stanford University.
William Bowes	Mr. William K. Bowes, Jr., is Independent Director of Xoma Corp., since February 1986. He has been a General Partner of U.S. Venture Partners since 1981 and currently holds the position of Founding Partner. Mr. Bowes is a member of the Board or the Business Advisory Council of a number of academic initiatives at institutions such as Harvard University, Stanford University, the University of California, San Francisco and the University of California, Berkeley. Mr. Bowes provides exceptional knowledge and advice on capital markets and development strategies for biopharmaceutical companies.
Peter Hutt	Mr. Peter Barton Hutt is Independent Director of Xoma Corp. He is former Chief Counsel for the Food and Drug Administration (FDA), became a director in May of 2005. Mr. Hutt is currently Senior Counsel to the Washington, D.C. law firm of Covington & Burling, specializing in food and drug law. Since 1994, he has taught a course on food and drug law at Harvard Law School and taught the same course at Stanford Law School in 1998. He is also a co-author of Food and Drug Law: Cases and Materials. Mr. Hutt is a member of the Institute of Medicine (IOM) of the National Academy of Sciences (NAS). He presently serves on the Working Group on Innovation in Drug Development and Evaluation of President Obama’s Council of Advisors on Science and Technology (PCAST). He has served on a wide variety of academic and advisory boards, including the Panel on the Administrative Restructuring of the National Institutes of Health (NIH). Formerly, he has served on the IOM Executive Committee, Advisory Committee to the Director of the NIH, the NAS Committee on Research Training in the Biomedical and Behavioral Sciences, and the National Committee to Review Current Procedures for Approval of New Drugs for Cancer and AIDS established by the President’s Cancer Panel of the National Cancer Institute at the request of President George Bush. Mr. Hutt received his undergraduate degree from Yale University, and law degrees from Harvard University and New York University. Mr. Hutt currently serves as a director of Ista Pharmaceuticals, and Momenta Pharmaceuticals.
Timothy Walbert	Mr. Timothy P. Walbert is Independent Director of Xoma Corp., since November 2010. Mr. Walbert is Chairman, President and Chief Executive Officer of Horizon Pharma. From 2007 until 2009, Mr. Walbert was President, Chief Executive Officer and a director of IDM Pharma, Inc. During his tenure, he drove the process of achieving European regulatory approval for MEPACT™ for the treatment of osteosarcoma, reorganized the company and its management team, and led the acquisition of IDM by Takeda America in June 2009. Prior to IDM, he was Executive Vice President of Commercial Operations for NeoPharm, Inc., a publicly traded biopharmaceutical company, where he oversaw global marketing, sales, reimbursement, manufacturing and business development. From 2001 to 2005, Mr. Walbert was with Abbott in positions of increasing responsibility, most recently as Vice President, International Marketing responsible for overseeing strategy for the global cardiovascular franchise. As Abbott’s Divisional Vice President and General Manager for Immunology, Mr. Walbert created and had full P&L management of the global immunology franchise that led the global development and launch of HUMIRA®. Prior to his tenure at Abbott, Mr. Walbert was with Searle/Pharmacia where he held several marketing roles for CELEBREX® in North America and coordinated international CELEBREX® launch and post-launch activities in key international markets. Mr. Walbert currently serves on the Board of Directors of Raptor Pharmaceutical Corp., the Board of the Biotechnology Industry organization, or BIO, the Board of the Illinois Biotechnology Association, or iBIO, and the Board of the Greater Chicago Arthritis Foundation. Mr. Walbert holds a B.A. degree from Muhlenberg College, Allentown, PA.
Jack Wyszomierski	Mr. Jack L. Wyszomierski is Independent Director of Xoma Corp., since August 2010. From 2004 until his retirement in 2009, Mr. Wyszomierski was Executive Vice President and Chief Financial Officer of VWR International, LLC, a global laboratory supply, equipment and distribution business that serves the world’s pharmaceutical and biotechnology companies, as well as industrial and governmental organizations. At Schering-Plough, a global health care company which had worldwide sales of over $8 billion in 2004, Mr. Wyszomierski held positions of increasing responsibility from 1982 to 2004 culminating in his appointment as Executive Vice President and Chief Financial Officer. Mr. Wyszomierski also serves on the Board of Directors of Athersys, Inc., Exelixis, Inc. and Unigene Laboratories, Inc. He holds an M.S. in Industrial Administration and a B.S. in Administration, Management Science and Economics from Carnegie Mellon University.

Basic Compensation

Name	Fiscal Year Total
W. Denman Van Ness	--
John Varian	434,298
Fred Kurland	861,458
Patrick Scannon	919,738
Paul Rubin	--
Tom Klein	--
Joseph Limber	--
Kelvin Neu	--
William Bowes	--
Peter Hutt	--
Timothy Walbert	--
Jack Wyszomierski	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
W. Denman Van Ness	0	0
John Varian	0	0
Fred Kurland	0	0
Patrick Scannon	375,000	191,528
Paul Rubin	0	0
Tom Klein	0	0
Joseph Limber	0	0
Kelvin Neu	0	0
William Bowes	0	0
Peter Hutt	0	0
Timothy Walbert	0	0
Jack Wyszomierski	0	0

Insider Trading

Name	Shares Traded	Price
VARIAN JOHN W	10,000	$1.24
VARIAN JOHN W	10,000	$4.20
SCANNON PATRICK J	10,000	$1.69
SCANNON PATRICK J	10,000	$4.31
RUBIN PAUL D	6,000	$3.29
RUBIN PAUL D	1,498	$3.32
RUBIN PAUL D	6,990	$3.29
RUBIN PAUL D	18,205	$0.00
SCANNON PATRICK J	4,455	$2.53
RUBIN PAUL D	833	$2.28
RUBIN PAUL D	2,214	$2.53
VARIAN JOHN W	4,455	$2.53
KURLAND FRED F	4,455	$2.53
VARIAN JOHN W	1,814	$2.56
VARIAN JOHN W	38,773	$2.56
KURLAND FRED F	9,111	$2.56
SCANNON PATRICK J	8,773	$2.56
SCANNON PATRICK J	22,653	$0.00
WALBERT TIMOTHY P	4,499	$0.00
VAN NESS W DENMAN	6,876	$0.00
WYSZOMIERSKI JACK L	4,499	$0.00
VARIAN JOHN W	96,167	$0.00
VARIAN JOHN W	4,499	$0.00
KURLAND FRED F	22,596	$0.00
BOWES WILLIAM K JR	4,499	$0.00

» Full list on Insider Trading

People: XOMA Corp (XOMA.W)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: